Browsing publications by Professor John Lunec

Newcastle AuthorsTitleYearFull text
Dr Nicholas Bown
Professor John Lunec
Professor Deborah Tweddle
Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification2015
Dr Ashleigh Herriott
Dr Susan Tudhope
Gesa Junge
Natalie Rodrigues
Dr Miranda Patterson
et al.
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia2015
Dr Lindi Chen
Professor Herbie Newell
Professor John Lunec
Professor Deborah Tweddle
Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma2015
Dr Andrey Zaytsev
Dr Barry Dodd
Professor Bernard Golding
Professor Roger Griffin
Dr Xiaohong Lu
et al.
Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach2015
Alex Liu
Dr Catherine Drummond
Professor Jane Endicott
Professor Bernard Golding
Professor Roger Griffin
et al.
An X-ray crystal structure-based understanding of the inhibition of the MDM2-p53 protein-protein interaction by isoindolinones2014
Dr Emma Bell
Dr Frida Ponthan
Claire Whitworth
Professor Deborah Tweddle
Professor John Lunec
et al.
COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib2014
Dr Jeffry Hogg
Jeremy French
Professor John Lunec
Nutlin-3 is cytotoxic in TP53 WT liposarcoma and leiomyosarcoma in vitro and can act both synergistically and antagonistically with ionising radiation2014
Dr Susan Tudhope
Dr Yan Zhao
Dr Anita Wittner
Annalisa Bertoli
Santosh Adhikari
et al.
Profiling inhibitors of MDM2: p53 and MDMX: p53 in relation to MDMX protein levels2014
Dr Lindi Chen
Dr Yan Zhao
Dr Gail Halliday
Philip Berry
Professor Herbie Newell
et al.
Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma2014
Professor John Lunec
The clinical development of p53-reactivating drugs in sarcomas - charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins2014
12345678910111213141516171819